Ignacio Romero

5PUBLICATIONS

66CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safety

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|May 12, 2026

Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.

|Dec 03, 2025

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Jan 03, 2025

No news, bad news: When the result of a clinical biomarker is "no result available".

Ignacio Romero

|Sep 05, 2023

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Ignace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton

|Aug 15, 2023

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham, Ignace Vergote, Susana Banerjee

Pageof 1

Frequent Collaborators

Ignace Vergote

Pauline Wimberger

Bradley J Monk

Mansoor Raza Mirza

Isabelle Ray-Coquard

Jose Alejandro Pérez-Fidalgo

Christian Marth

David Cibula

Rachel N Grisham

Elsa Kalbacher

Frequent Collaborators

Ignace Vergote

Pauline Wimberger

Bradley J Monk

Mansoor Raza Mirza